Drug shortage
Dextrose Monohydrate 50% Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · Current · updated Apr 11, 2025
Key facts
| Generic name | Dextrose Monohydrate 50% Injection |
|---|---|
| Proprietary name | Dextrose Monohydrate 50% |
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02) |
| Dosage form | Injection |
| Strength | 25 g/50 mL |
| Status | Current |
| Therapeutic category | Endocrinology/Metabolism Gastroenterology Pediatric |
| Package NDCs | 0409-6648-02 |
| First posted | Jan 13, 2022 |
| Last updated | Apr 11, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: